Cartesian Therapeutics (RNAC) Tax Provisions (2021 - 2022)
Cartesian Therapeutics' (RNAC) quarterly Tax Provisions came in at -$288000.0 in Q4 2022, down 308.7% year-on-year from $138000.0 in Q4 2021, and up 10.28% on a QoQ basis from -$321000.0 in Q3 2022.
Cartesian Therapeutics (RNAC) Tax Provisions (2021 - 2022) Analysis & Trends
Cartesian Therapeutics (RNAC) has 2 years of Tax Provisions data on file, last reported at -$288000.0 in Q4 2022.
- On a quarterly basis, Tax Provisions fell 308.7% year-over-year to -$288000.0 in Q4 2022; TTM through Dec 2022 was $15.4 million, a 3.81% decrease from a year earlier, with the FY2025 full-year figure at -$9.2 million, down 3166.67% from the prior year.
- Tax Provisions for Q4 2022 stood at -$288000.0, up from -$321000.0 in the prior quarter.
- Over the last five years, Tax Provisions for RNAC reached as high as $15.8 million in Q3 2021 and fell as low as -$321000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 125,146.46 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 31.86 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 188,883.60 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 221.50 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 179.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cartesian Therapeutics | 226.07 Mn | 226.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -288,000.00 |
| Sep 30, 2022 | -321,000.00 |
| Dec 31, 2021 | 138,000.00 |
| Sep 30, 2021 | 15.83 Mn |